Acute neurocognitive response to methylphenidate among survivors of childhood cancer: A randomized, double-blind, cross-over trial

Heather M. Conklin, Raja B. Khan, Wilburn E. Reddick, Susan Helton, Ronald Brown, Scott C. Howard, Melanie Bonner, Robbin Christensen, Shengjie Wu, Xiaoping Xiong, Raymond K. Mulhern

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Objective: To investigate the acute efficacy and adverse side effects of methylphenidate (MPH) among survivors of childhood cancer [acute lymphoblastic leukemia (ALL) or brain tumor (BT)] with learning impairments. Methods: Participants (N = 122) completed a two-day, in-clinic, double-blind, cross-over trial during which they received MPH (0.60 mg/kg of body weight) and placebo that were randomized in administration order across participants. Performance was evaluated using measures of attention, memory, and academic achievement. Results: A significant MPH versus placebo effect was revealed on a measure of attention, cognitive flexibility, and processing speed (Stroop Word-Color Association Test). Male gender, older age at treatment, and higher intelligence were predictive of better medication response. No significant differences were found for number or severity of adverse side effects as a function of active medication. Conclusions: MPH shows some neurocognitive benefit and is well tolerated by the majority of children surviving ALL and BT.

Original languageEnglish (US)
Pages (from-to)1127-1139
Number of pages13
JournalJournal of pediatric psychology
Volume32
Issue number9
DOIs
StatePublished - Oct 1 2007

Fingerprint

Methylphenidate
Cross-Over Studies
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Brain Neoplasms
Neoplasms
Word Association Tests
Placebo Effect
Intelligence
Color
Placebos
Body Weight
Learning
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Developmental and Educational Psychology

Cite this

Acute neurocognitive response to methylphenidate among survivors of childhood cancer : A randomized, double-blind, cross-over trial. / Conklin, Heather M.; Khan, Raja B.; Reddick, Wilburn E.; Helton, Susan; Brown, Ronald; Howard, Scott C.; Bonner, Melanie; Christensen, Robbin; Wu, Shengjie; Xiong, Xiaoping; Mulhern, Raymond K.

In: Journal of pediatric psychology, Vol. 32, No. 9, 01.10.2007, p. 1127-1139.

Research output: Contribution to journalArticle

Conklin, HM, Khan, RB, Reddick, WE, Helton, S, Brown, R, Howard, SC, Bonner, M, Christensen, R, Wu, S, Xiong, X & Mulhern, RK 2007, 'Acute neurocognitive response to methylphenidate among survivors of childhood cancer: A randomized, double-blind, cross-over trial', Journal of pediatric psychology, vol. 32, no. 9, pp. 1127-1139. https://doi.org/10.1093/jpepsy/jsm045
Conklin, Heather M. ; Khan, Raja B. ; Reddick, Wilburn E. ; Helton, Susan ; Brown, Ronald ; Howard, Scott C. ; Bonner, Melanie ; Christensen, Robbin ; Wu, Shengjie ; Xiong, Xiaoping ; Mulhern, Raymond K. / Acute neurocognitive response to methylphenidate among survivors of childhood cancer : A randomized, double-blind, cross-over trial. In: Journal of pediatric psychology. 2007 ; Vol. 32, No. 9. pp. 1127-1139.
@article{062f162dc7c54164945f6ebc81badd03,
title = "Acute neurocognitive response to methylphenidate among survivors of childhood cancer: A randomized, double-blind, cross-over trial",
abstract = "Objective: To investigate the acute efficacy and adverse side effects of methylphenidate (MPH) among survivors of childhood cancer [acute lymphoblastic leukemia (ALL) or brain tumor (BT)] with learning impairments. Methods: Participants (N = 122) completed a two-day, in-clinic, double-blind, cross-over trial during which they received MPH (0.60 mg/kg of body weight) and placebo that were randomized in administration order across participants. Performance was evaluated using measures of attention, memory, and academic achievement. Results: A significant MPH versus placebo effect was revealed on a measure of attention, cognitive flexibility, and processing speed (Stroop Word-Color Association Test). Male gender, older age at treatment, and higher intelligence were predictive of better medication response. No significant differences were found for number or severity of adverse side effects as a function of active medication. Conclusions: MPH shows some neurocognitive benefit and is well tolerated by the majority of children surviving ALL and BT.",
author = "Conklin, {Heather M.} and Khan, {Raja B.} and Reddick, {Wilburn E.} and Susan Helton and Ronald Brown and Howard, {Scott C.} and Melanie Bonner and Robbin Christensen and Shengjie Wu and Xiaoping Xiong and Mulhern, {Raymond K.}",
year = "2007",
month = "10",
day = "1",
doi = "10.1093/jpepsy/jsm045",
language = "English (US)",
volume = "32",
pages = "1127--1139",
journal = "Journal of Pediatric Psychology",
issn = "0146-8693",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Acute neurocognitive response to methylphenidate among survivors of childhood cancer

T2 - A randomized, double-blind, cross-over trial

AU - Conklin, Heather M.

AU - Khan, Raja B.

AU - Reddick, Wilburn E.

AU - Helton, Susan

AU - Brown, Ronald

AU - Howard, Scott C.

AU - Bonner, Melanie

AU - Christensen, Robbin

AU - Wu, Shengjie

AU - Xiong, Xiaoping

AU - Mulhern, Raymond K.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Objective: To investigate the acute efficacy and adverse side effects of methylphenidate (MPH) among survivors of childhood cancer [acute lymphoblastic leukemia (ALL) or brain tumor (BT)] with learning impairments. Methods: Participants (N = 122) completed a two-day, in-clinic, double-blind, cross-over trial during which they received MPH (0.60 mg/kg of body weight) and placebo that were randomized in administration order across participants. Performance was evaluated using measures of attention, memory, and academic achievement. Results: A significant MPH versus placebo effect was revealed on a measure of attention, cognitive flexibility, and processing speed (Stroop Word-Color Association Test). Male gender, older age at treatment, and higher intelligence were predictive of better medication response. No significant differences were found for number or severity of adverse side effects as a function of active medication. Conclusions: MPH shows some neurocognitive benefit and is well tolerated by the majority of children surviving ALL and BT.

AB - Objective: To investigate the acute efficacy and adverse side effects of methylphenidate (MPH) among survivors of childhood cancer [acute lymphoblastic leukemia (ALL) or brain tumor (BT)] with learning impairments. Methods: Participants (N = 122) completed a two-day, in-clinic, double-blind, cross-over trial during which they received MPH (0.60 mg/kg of body weight) and placebo that were randomized in administration order across participants. Performance was evaluated using measures of attention, memory, and academic achievement. Results: A significant MPH versus placebo effect was revealed on a measure of attention, cognitive flexibility, and processing speed (Stroop Word-Color Association Test). Male gender, older age at treatment, and higher intelligence were predictive of better medication response. No significant differences were found for number or severity of adverse side effects as a function of active medication. Conclusions: MPH shows some neurocognitive benefit and is well tolerated by the majority of children surviving ALL and BT.

UR - http://www.scopus.com/inward/record.url?scp=35448967450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448967450&partnerID=8YFLogxK

U2 - 10.1093/jpepsy/jsm045

DO - 10.1093/jpepsy/jsm045

M3 - Article

C2 - 17569711

AN - SCOPUS:35448967450

VL - 32

SP - 1127

EP - 1139

JO - Journal of Pediatric Psychology

JF - Journal of Pediatric Psychology

SN - 0146-8693

IS - 9

ER -